{
  "abstract": "Data on cabozantinib monotherapy for metastatic renal cell carcinoma in patients requiring hemodialysis are scarce. We present two cases: initiation before hemodialysis with subsequent continuation and initiation during maintenance hemodialysis. Case 1 was a 77-year-old man with lung metastasis who received cabozantinib after multiple systemic therapies. Cabozantinib was started at 20 mg/day before hemodialysis; hemodialysis began 8 months later, and treatment continued for 59 months with tolerability-guided schedule modification. Case 2 was a 69-year-old man on maintenance hemodialysis who received cabozantinib 20 mg/day for lung and bone metastases. The schedule was changed to alternate-day dosing. Partial response was achieved, but treatment was discontinued after 4 months because of worsening general condition. Cabozantinib was administered with individualized dose adjustment and careful monitoring; further clinical and pharmacokinetic data are needed to establish optimal dosing.",
  "abstract_shown": true,
  "affiliations": [
    "Department of Urology Japanese Red Cross Akita Hospital Akita City Japan.",
    "Department of Urology Akita University Graduate School of Medicine Akita City Japan."
  ],
  "article_type": null,
  "arxiv": null,
  "author_total": 7,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Taketoshi Nara",
      "orcid": "0009-0005-0605-9972"
    },
    {
      "affs": [
        1
      ],
      "name": "Kengo Furihata"
    },
    {
      "affs": [
        1
      ],
      "name": "Kazuma Sato"
    },
    {
      "affs": [
        0
      ],
      "name": "Takuma Sato"
    },
    {
      "affs": [
        0
      ],
      "name": "Naoko Honma"
    },
    {
      "affs": [
        0
      ],
      "name": "Yohei Horikawa"
    },
    {
      "affs": [
        0
      ],
      "name": "Naotake Shimoda"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/4qxq1n3kmdps6.bib",
  "cited_by": 0,
  "doi": "10.1002/iju5.70291",
  "fulltext_url": "https://europepmc.org/articles/PMC13741850",
  "id": "4qxq1n3kmdps6",
  "issns": [
    "2577-171X"
  ],
  "landing_url": "https://europepmc.org/article/MED/42997484",
  "language": "eng",
  "licence": "CC-BY-NC",
  "licence_label": "CC BY-NC",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by-nc/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "openalex",
      "2730|Renal cell carcinoma treatment"
    ]
  ],
  "openalex": "W7225416459",
  "pdf_url": "https://europepmc.org/articles/PMC13741850?pdf=render",
  "pmcid": "PMC13741850",
  "pmid": "42997484",
  "published": "2026-11-06",
  "publisher": null,
  "ris": "https://research.draconitic.com/paper/4qxq1n3kmdps6.ris",
  "sources": [
    {
      "first_seen": "2026-11-09T15:20:34Z",
      "native_id": "MED:42997484",
      "source": "europepmc",
      "url": "https://europepmc.org/article/MED/42997484"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2730|Renal cell carcinoma treatment",
      "subfield": "oncology"
    }
  ],
  "title": "Cabozantinib Monotherapy for Metastatic Renal Cell Carcinoma Involving Hemodialysis: Two Case Reports.",
  "title_text": "Cabozantinib Monotherapy for Metastatic Renal Cell Carcinoma Involving Hemodialysis: Two Case Reports.",
  "type": "peer-reviewed",
  "updated_at": "2026-11-09T15:20:34Z",
  "url": "https://research.draconitic.com/paper/4qxq1n3kmdps6",
  "venue": "IJU case reports",
  "versions": []
}